Perrigo fiscal 1996 sales grow 9%, fueled by OTCs, nutritionals.
This article was originally published in The Tan Sheet
PERRIGO FY 1996 SALES INCREASE 9% BUOYED BY GROWING NUTRITIONALS BUSINESS and rising OTC drug sales, the private-label manufacturer reported Aug. 14. Sales for the fiscal year ended June 30 rose to $778.1 mil., up from $717.1 mil. in FY 1995. However, net profits for fiscal 1996 slumped, falling 10.3% to $39.8 mil
You may also be interested in...
If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.